In this article
Eli Lilly
on Friday said it will spend more than $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs.
That includes a closely watched experimental drug called retatrutide, which has shown the highest weight loss seen to date for any treatment in a late-stage trial.
It is the fourth facility in a string of new planned U.S. investments by the pharmaceutical giant. Lilly announced in February 2025 that it would spend at least $27 billion to build new domestic manufacturing facilities, adding to $23 billion in previous investments since 2020.
